JP2011502966A5 - - Google Patents

Download PDF

Info

Publication number
JP2011502966A5
JP2011502966A5 JP2010531330A JP2010531330A JP2011502966A5 JP 2011502966 A5 JP2011502966 A5 JP 2011502966A5 JP 2010531330 A JP2010531330 A JP 2010531330A JP 2010531330 A JP2010531330 A JP 2010531330A JP 2011502966 A5 JP2011502966 A5 JP 2011502966A5
Authority
JP
Japan
Prior art keywords
dopamine transporter
patient
composition
ligand
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010531330A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502966A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/081569 external-priority patent/WO2009058851A2/en
Publication of JP2011502966A publication Critical patent/JP2011502966A/ja
Publication of JP2011502966A5 publication Critical patent/JP2011502966A5/ja
Pending legal-status Critical Current

Links

JP2010531330A 2007-10-31 2008-10-29 ドーパミントランスポーターレベルを評価することによるレビー小体型認知症の診断およびレビー小体型認知症の処置のモニタリングのための方法 Pending JP2011502966A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98419407P 2007-10-31 2007-10-31
PCT/US2008/081569 WO2009058851A2 (en) 2007-10-31 2008-10-29 Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level

Publications (2)

Publication Number Publication Date
JP2011502966A JP2011502966A (ja) 2011-01-27
JP2011502966A5 true JP2011502966A5 (enExample) 2012-11-15

Family

ID=40591729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010531330A Pending JP2011502966A (ja) 2007-10-31 2008-10-29 ドーパミントランスポーターレベルを評価することによるレビー小体型認知症の診断およびレビー小体型認知症の処置のモニタリングのための方法

Country Status (5)

Country Link
US (2) US20100312105A1 (enExample)
EP (1) EP2211911A4 (enExample)
JP (1) JP2011502966A (enExample)
CA (1) CA2703563A1 (enExample)
WO (1) WO2009058851A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009040727A2 (en) * 2007-09-26 2009-04-02 Philips Intellectual Property & Standards Gmbh Method of differentially diagnosing different types of dementia
KR20160138339A (ko) * 2013-03-15 2016-12-05 아담 제이 사이먼 뇌 건강의 다중-모드 약리-진단 평가
WO2014143896A2 (en) 2013-03-15 2014-09-18 Simon Adam J System and signatures for the multi-modal physiological stimulation and assessment of brain health
GB201313291D0 (en) * 2013-07-25 2013-09-11 Ge Healthcare Ltd Imaging neurological disease
CN104720840A (zh) * 2015-02-11 2015-06-24 清华大学深圳研究生院 基于多巴胺转运体显像特异性摄取比的半自动量化方法
EP3579887A4 (en) * 2017-02-10 2020-09-16 Likeminds, Inc. PROCEDURE FOR IN VIVO MONITORING OF DOPAMINER DISORDERS AND EFFECTIVENESS OF TREATMENT PRODUCTS THEREFORE
WO2020018743A1 (en) * 2018-07-18 2020-01-23 Likeminds, Inc. Method for accelerated tissue penetration of compounds into brain
AU2019319837A1 (en) * 2018-08-07 2021-02-25 Likeminds, Inc. Method for diagnosis of dopaminergic and movement disorders
TWI686178B (zh) * 2019-10-09 2020-03-01 中原大學 自動化定位核子醫學腦部影像紋狀體與計算紋狀體專一性攝取率的方法與系統
WO2021092096A1 (en) * 2019-11-06 2021-05-14 Likeminds, Inc. Individualized dosing of radioactive tracers for imaging
WO2022240817A1 (en) * 2021-05-13 2022-11-17 Likeminds, Inc. Methods of visualizing dopamine transporters

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081238B2 (en) * 1995-11-03 2006-07-25 The President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
CA2304505A1 (en) * 1997-09-24 1999-04-01 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
AU2001249091A1 (en) * 2000-03-03 2001-09-17 Eisai Co. Ltd. Novel methods using cholinesterase inhibitors
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
AU2003291358A1 (en) * 2002-11-07 2004-06-03 Molecular Geriatrics Corporation Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease
US20080302950A1 (en) * 2005-08-11 2008-12-11 The Brigham And Women's Hospital, Inc. System and Method for Performing Single Photon Emission Computed Tomography (Spect) with a Focal-Length Cone-Beam Collimation
CA2628108C (en) * 2005-11-10 2020-01-07 Certara Usa, Inc. Method and apparatus for computer modeling the human brain for predicting drug effects
EP2604290A3 (en) * 2006-05-02 2013-07-10 The Trustees of The University of Pennsylvania Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents
WO2009040727A2 (en) * 2007-09-26 2009-04-02 Philips Intellectual Property & Standards Gmbh Method of differentially diagnosing different types of dementia
US8084018B2 (en) * 2007-10-31 2011-12-27 Alseres Pharmaceuticals, Inc. Methods for imaging dopamine transporter level
US8557222B2 (en) * 2008-04-04 2013-10-15 Avid Radiopharmaceuticals, Inc. Radiopharmaceutical imaging of neurodegenerative diseases
EP3521309A1 (en) * 2008-12-19 2019-08-07 Biogen International Neuroscience GmbH Human anti-alpha-synuclein antibodies
CA2764387A1 (en) * 2009-06-05 2010-12-09 Link Medicine Corporation Aminopyrrolidinone derivatives and uses thereof
GB0922304D0 (en) * 2009-12-22 2010-02-03 Ge Healthcare Ltd Radioiodinated compounds

Similar Documents

Publication Publication Date Title
JP2011502966A5 (enExample)
Mueller et al. Tau PET imaging with 18F-PI-2620 in patients with Alzheimer disease and healthy controls: a first-in-humans study
JP5603855B2 (ja) 神経変成疾患の放射性薬剤による画像化
US20100312105A1 (en) Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level
Zhu et al. PET/SPECT imaging agents for neurodegenerative diseases
Ossenkoppele et al. Longitudinal imaging of Alzheimer pathology using [11C] PIB,[18F] FDDNP and [18F] FDG PET
AU2019253837B2 (en) Imaging neurological disease
Henderson The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging
JP2014148529A (ja) ドーパミン輸送体レベルを造影するための方法
Koric et al. Molecular imaging in the diagnosis of Alzheimer's disease and related disorders
Villemagne et al. Amyloid imaging
Romano et al. Florbetapir F 18 for brain imaging of beta-amyloid plaques
US20210162078A1 (en) Method for diagnosis of dopaminergic and movement disorders
Suppiah et al. diagnostics MDPI
Chiotis Molecular imaging of tau in the pathological cascade of Alzheimer’s disease
Coakeley PET Imaging of Pathological Tau in Progressive Supranuclear Palsy
Koopmans et al. 18F DOPA PET/CT in Neuroendocrine Tumours and in Presynaptic Dopaminergic Deficits
US20230001026A1 (en) Pharmaceutical packaging units and methods for concomitant administration of radiotracers
Marek Preclinical properties and humanin vivoassessment of123I-ABC577 as a novel SPECT agent for imaging amyloid-β
Ponto Positron Emission Tomography (PET) Imaging: Principles and Potential Role in Understanding Brain Function
Scheinin EARLY DETECTION OF ALZHEIMER’S DISEASE β-AMYLOID PATHOLOGY
Nair et al. Amyloid imaging
Ossenkoppele et al. Longitudinal Imaging of Alzheimer Pathology using [P
VLV et al. Regional variability of imaging biomarkers in autosomal dominant AlzheimerTs disease
JP2003503325A (ja) 注意欠陥多動性障害（ａｄ−ｈｄ）を決定するためのドーパミントランスポータの映像化